期刊
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 20, 期 12, 页码 1415-1430出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1871520620666200422073622
关键词
Melanoma; BRAF; MAPK; inhibitors; mechanisms of resistance; immunotherapy
资金
- National Natural Science Foundation of China [21602042]
- Fundamental Research Funds for the Central Universities of China [JZ2019HGTB0062]
- Key Scientific and Technological Project of Anhui Provincial Tobacco Company [20160551008]
Background: Almost 50% of metastatic melanomas harbor BRAF mutations. Since 2011, BRAF inhibitors have exhibited striking clinical benefits in BRAF-mutant melanoma patients. Unfortunately, their therapeutic effects are often temporary. The resistance mechanisms vary and can be broadly classified as MAPK reactivation-dependent and-independent. Elucidation of these resistance mechanisms provides new insights into strategies for overcoming resistance. Indeed, several alternative treatment strategies, including changes in the mode of administration, combinations of BRAF and MEK inhibitors, and immunotherapy have been verified as beneficial to BRAF inhibitor-resistant melanoma patients. Prospect: In this review, we discuss promising strategies for overcoming drug resistance and highlighting the prospects for discovering strategies to counteract BRAF inhibitor resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据